Evidence map›Paper›PMID 42272965›Full record

ArticleBioengineering & translational medicine2026

Development of a novel methyl cellulose hydrogel with physiologically relevant controlled ethanol release for cervical dysplasia ablation.

Ashleigh M Jankowski, Erela Imanoel, Gatha Adhikari, Jenna Mueller, Katharina Maisel

Abstract read
In one paragraph

Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ashleigh M JankowskiFischell Department of Bioengineering University of Maryland College Park Maryland USA.ORCID https://orcid.org/0000-0003-2160-990X
Erela ImanoelFischell Department of Bioengineering University of Maryland College Park Maryland USA.
Gatha AdhikariFischell Department of Bioengineering University of Maryland College Park Maryland USA.ORCID https://orcid.org/0000-0002-3832-8832
Jenna MuellerFischell Department of Bioengineering University of Maryland College Park Maryland USA.
Katharina MaiselFischell Department of Bioengineering University of Maryland College Park Maryland USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is a leading cause of death in women in low- and middle-income countries (LMICs) and disproportionately affects women of minority populations in the United States, primarily due to a lack of infrastructural support for specialized care. A promising treatment that meets accessibility requirements is ethyl cellulose (EC)-ethanol ablation-inducing necrotic cell death through application of ethanol to kill precancerous cells. While previous work focused on injecting EC-ethanol to ablate high-grade dysplasia (which can reach depths up to 5 mm below the tissue surface), low-grade dysplasia requires a different delivery method as it is much more superficial (reaching depths of only 1-3 mm). Here, we have developed a topical gel for local ethanol ablation of low-grade dysplasia with minimal damage to healthy cervical tissue. We investigated several gellants, including methyl cellulose (MC), EC, and Pluronic® F-127, to develop an ethanol gel that meets parameters for low cost and topical ease of use. Formulations with F-127 did not form gels with ethanol. Formulations with EC and MC were gel-forming. The MC-based formulations formed more uniform and stable gels that hold their own weight while still being spreadable at both room and body temperatures, key criteria for local cervical application. The optimal formulation contained 70% ethanol, 20% water, and 10% MC. One gram of this formulation represents approximately 5¢ material cost, and formulated gels were stable for at least 1 week when stored at 4, 22, 30, and 37°C. Additionally, the MC gel achieved localized ablation within 5 min after application to cervical cancer cells in vitro. Taken together, we have developed a low-cost, efficacious, MC-based ethanol gel fit for translational testing to treat low-grade cervical dysplasia. This gel may provide a novel treatment option for women in LMICs, without causing major side effects or loss of healthy cervical tissue.

Indexed as

cervical dysplasiaethanol ablationtopical gel

Identifiers

PMID42272965
PMCPMC13247434

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.